These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 30343280)

  • 1. Evaluation of the Insulin-like Growth Factor Receptor Pathway in Patients with Advanced Breast Cancer Treated with Trastuzumab.
    Christodoulou C; Oikonomopoulos G; Koliou GA; Kostopoulos I; Kotoula V; Bobos M; Pentheroudakis G; Lazaridis G; Skondra M; Chrisafi S; Koutras A; Bafaloukos D; Razis E; Papadopoulou K; Papakostas P; Kalofonos HP; Pectasides D; Skarlos P; Kalogeras KT; Fountzilas G
    Cancer Genomics Proteomics; 2018; 15(6):461-471. PubMed ID: 30343280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study.
    Koutras A; Lazaridis G; Koliou GA; Kouvatseas G; Christodoulou C; Pectasides D; Kotoula V; Batistatou A; Bobos M; Tsolaki E; Papadopoulou K; Pentheroudakis G; Papakostas P; Pervana S; Petraki K; Chrisafi S; Razis E; Psyrri A; Bafaloukos D; Kalogeras KT; Kalofonos HP; Fountzilas G
    PLoS One; 2018; 13(12):e0207707. PubMed ID: 30521571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin-like growth factor-1 receptor signaling increases the invasive potential of human epidermal growth factor receptor 2-overexpressing breast cancer cells via Src-focal adhesion kinase and forkhead box protein M1.
    Sanabria-Figueroa E; Donnelly SM; Foy KC; Buss MC; Castellino RC; Paplomata E; Taliaferro-Smith L; Kaumaya PT; Nahta R
    Mol Pharmacol; 2015 Feb; 87(2):150-61. PubMed ID: 25391374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer.
    Köstler WJ; Hudelist G; Rabitsch W; Czerwenka K; Müller R; Singer CF; Zielinski CC
    J Cancer Res Clin Oncol; 2006 Jan; 132(1):9-18. PubMed ID: 16184380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.
    Luen SJ; Salgado R; Fox S; Savas P; Eng-Wong J; Clark E; Kiermaier A; Swain SM; Baselga J; Michiels S; Loi S
    Lancet Oncol; 2017 Jan; 18(1):52-62. PubMed ID: 27964843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nuclear Gli1 expression is associated with pathological complete response and event-free survival in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant therapy.
    Liu S; Duan X; Xu L; Ye J; Cheng Y; Liu Q; Zhang H; Zhang S; Zhu S; Li T; Liu Y
    Tumour Biol; 2016 Apr; 37(4):4873-81. PubMed ID: 26526577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer.
    Koo DH; Lee HJ; Ahn JH; Yoon DH; Kim SB; Gong G; Son BH; Ahn SH; Jung KH
    Tumour Biol; 2015 Aug; 36(8):5865-71. PubMed ID: 25725586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
    Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
    Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. t-Darpp Activates IGF-1R Signaling to Regulate Glucose Metabolism in Trastuzumab-Resistant Breast Cancer Cells.
    Lenz G; Hamilton A; Geng S; Hong T; Kalkum M; Momand J; Kane SE; Huss JM
    Clin Cancer Res; 2018 Mar; 24(5):1216-1226. PubMed ID: 29180608
    [No Abstract]   [Full Text] [Related]  

  • 11. Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.
    Grell P; Fabian P; Khoylou M; Radova L; Slaby O; Hrstka R; Vyzula R; Hajduch M; Svoboda M
    Int J Oncol; 2012 Oct; 41(4):1204-12. PubMed ID: 22842582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
    Krop IE; Kim SB; Martin AG; LoRusso PM; Ferrero JM; Badovinac-Crnjevic T; Hoersch S; Smitt M; Wildiers H
    Lancet Oncol; 2017 Jun; 18(6):743-754. PubMed ID: 28526538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The level of insulin growth factor-1 receptor expression is directly correlated with the tumor uptake of (111)In-IGF-1(E3R) in vivo and the clonogenic survival of breast cancer cells exposed in vitro to trastuzumab (Herceptin).
    Cornelissen B; McLarty K; Kersemans V; Reilly RM
    Nucl Med Biol; 2008 Aug; 35(6):645-53. PubMed ID: 18678349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab.
    Blanchette PS; Desautels DN; Pond GR; Bartlett JMS; Nofech-Mozes S; Yaffe MJ; Pritchard KI
    Breast Cancer Res Treat; 2018 Jul; 170(1):169-177. PubMed ID: 29520532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients.
    Koumarianou A; Karayannopoulou G; Gourgioti G; Batistatou A; Bobos M; Efstratiou I; Miliaras D; Galani E; Pentheroudakis G; Pectasides D; Aravantinos G; Bafaloukos D; Papakostas P; Razis E; Kalofonos HP; Petraki K; Sotiropoulou M; Kalogeras KT; Fountzilas G
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1289-301. PubMed ID: 25947084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer.
    Takada K; Kashiwagi S; Goto W; Asano Y; Morisaki T; Fujita H; Takashima T; Ohsawa M; Hirakawa K; Ohira M
    Anticancer Res; 2018 Apr; 38(4):2285-2294. PubMed ID: 29599351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells.
    Lyu H; Yang XH; Edgerton SM; Thor AD; Wu X; He Z; Liu B
    Oncotarget; 2016 Jan; 7(3):2921-35. PubMed ID: 26621843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
    Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
    Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.
    Lambertini M; Ferreira AR; Di Meglio A; Poggio F; Puglisi F; Sottotetti F; Montemurro F; Poletto E; Bernardo A; Risi E; Dellepiane C; Sini V; Minuti G; Grasso D; Fancelli S; Del Mastro L
    Clin Breast Cancer; 2017 Dec; 17(8):601-610.e2. PubMed ID: 28479052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Racial differences in outcomes for patients with metastatic breast cancer by disease subtype.
    Vaz-Luis I; Lin NU; Keating NL; Barry WT; Lii H; Winer EP; Freedman RA
    Breast Cancer Res Treat; 2015 Jun; 151(3):697-707. PubMed ID: 26022349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.